Clinical trials: Succinic Semialdehyde Dehydrogenase
Succinic Semialdehyde Dehydrogenase Deficiency, SSADH Deficiency
PET Imaging of GABA Receptors in Succinic Semialdehyde Dehydrogenase Deficiency
This study will use brain imaging to map brain cell receptors for a chemical called GABA, a chemical that inhibits the activities of nerve cells.
- Trial name
- NCT00246870
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Succinic Semialdehyde Dehydrogenase Deficiency
Natural History Study of Patients With Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency
Succinic Semialdehyde Dehydrogenase deficiency (SSADHD) is a rare autosomal recessive disease that interferes with the catabolism of the major inhibitory neurotransmitter gamma-amino butyric acid (GABA) and furthermore leads to…
- Trial name
- NCT03758521
- Testing
- Transcranial magnetic stimulation (TMS), Magnetic resonance imaging (MRI), Electroencephalogram (EEG)
- Where
- 4 sites in United States, Germany and 2 more
- Volunteers
- 55 people
- Sponsor
- Boston Children's Hospital
Succinic Semialdehyde Dehydrogenase
Taurine Therapy for SSADH Deficiency
Background: Succinic semialdehyde dehydrogenase (SSADH) deficiency is a rare genetic disease that results in changes to certain brain chemicals.
- Trial name
- NCT01608178
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Succinic Semialdehyde, Dehydrogenase Deficiency
Brain Excitability in Patients With Succinic Semialdehyde Dehydrogenase Deficiency
This study will measure brain excitability in patients with succinic semialdehyde dehydrogenase (SSADH) deficiency, and in their parents.
- Conditions
- Succinic Semialdehyde, Dehydrogenase Deficiency, Diseases
- Trial name
- NCT00132366
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Metabolic Disease, Seizures
Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
Objective: To perform a clinical trial assessing the safety, tolerability and efficacy of the GABA(B) receptor antagonist SGS-742 in patients with SSADH deficiency.
- Trial name
- NCT02019667
- Testing
- SGS-742
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)